Determination of intranasal allergen threshold to egg in children with egg allergy
ISRCTN | ISRCTN11376766 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN11376766 |
Secondary identifying numbers | 15942 |
- Submission date
- 16/01/2014
- Registration date
- 16/01/2014
- Last edited
- 11/05/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Ms Christine Buicke
Scientific
Scientific
Joint Research Compliance Office
Charing Cross Hospital
Fulham Palace Road
London
W6 8RF
United Kingdom
Phone | +44 20 7589 5111 |
---|---|
c.buicke@imperial.ac.uk |
Study information
Study design | Non-randomised; Interventional; Design type: Diagnosis, Not specified, Prevention |
---|---|
Primary study design | Interventional |
Secondary study design | Non randomised controlled trial |
Study setting(s) | Hospital |
Study type | Other |
Scientific title | Determination of intranasal allergen threshold to egg in children with egg allergy |
Study acronym | INATE Study |
Study objectives | Determination of intranasal allergen threshold to egg in children with egg allergy |
Ethics approval(s) | 14/WM/0016 |
Health condition(s) or problem(s) studied | Topic: Medicines for Children Research Network; Subtopic: All Diagnoses; Disease: All Diseases |
Intervention | Primary Intervention, Sequential, incremental doses of aerosolised (food grade) egg white (egg protein) at 0, 0.1, 1, 10 and (where no symptoms are present) 100 µg per nostril (in sterile normal saline), at 30 minute intervals, using a nasal spray. |
Intervention type | Other |
Primary outcome measure | Immediate allergic reaction (<30mins following administration) |
Secondary outcome measures | Not provided at time of registration |
Overall study start date | 06/01/2014 |
Completion date | 03/10/2014 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Child |
Lower age limit | 6 Years |
Upper age limit | 17 Years |
Sex | Both |
Target number of participants | Planned Sample Size: 12; UK Sample Size: 12 |
Key inclusion criteria | 1. Aged 6 - 17 years old 2. Physiciandiagnosis of egg allergy on the basis of: Positive oral food challenge to egg (conducted under medical supervision) within the last 12 months OR History of convincing clinical reaction to egg within the last 12 months AND positive skin prick test within last 6 months OR Evidence of >95% likelihood of egg allergy (on the basis of serum specific IgE 6.0 IU/mL or above or skin prick test (SPT) 6mm or above to egg white within past 12 months but with no history of oral tolerance to egg 3. Written informed consent from parent/guardian, with assent from children aged 8 years and above wherever possible. |
Key exclusion criteria | 1. Contraindicated as acutely unwell or current unstable asthma 1.1. Acute wheeze in last 72 hours requiring treatment 1.2. Febrile =380 deg C in last 72 hours 1.3. Recent admission to hospital in last 2 weeks for acute asthma 2. Current medication 2.1. Use of asthma reliever medication in last 72 hours 2.2. Recent administration of a medication containing antihistamine within the last 4 days 2.3. Current oral steroid for asthma exacerbation or course completed within last 2 weeks |
Date of first enrolment | 06/01/2014 |
Date of final enrolment | 03/10/2014 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Joint Research Compliance Office
London
W6 8RF
United Kingdom
W6 8RF
United Kingdom
Sponsor information
Imperial College London (UK)
University/education
University/education
Joint Research Compliance Office
Charing Cross Hospital
Fulham Palace Road
London
W6 8RF
England
United Kingdom
https://ror.org/041kmwe10 |
Funders
Funder type
Government
Public Health England (PHE) (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- PHE
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
11/05/2017: No publications found in PubMed, verifying study status with principal investigator